The GSEA study showed that ELOVL1 participated antigen processing and presentation (ES = 0.8987, NP = 0.0048), pathways in cancer (ES = 0.6627, NP=0.0124), leukocyte transendothelial migration (ES = 0.7697, NP = 0.0136), NOD-like receptor signaling pathway (ES = 0.8072, NP = 0.0187), and Toll-like receptor signaling pathway (ES = 0.7631, NP = 0.0260) (Supplementary Figure 1). Here, ELOVL1 is linked to cancer.